[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]

Presse Med. 2011 Apr;40(4 Pt 1):371-8. doi: 10.1016/j.lpm.2011.02.001. Epub 2011 Mar 21.
[Article in French]

Abstract

Smoking status is essential to know when taking care of a lung cancer patient. Never-smoking patients account for 15% of lung cancer patients, more often women and adenocarcinoma. Environmental tobacco smoke and occupational exposure could be important risk factors. Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations. New molecular targets are on investigation, such as EML4-ALK translocation. Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / epidemiology*
  • Adenocarcinoma / genetics*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Bronchogenic / drug therapy
  • Carcinoma, Bronchogenic / epidemiology*
  • Carcinoma, Bronchogenic / genetics*
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / epidemiology*
  • Carcinoma, Squamous Cell / genetics*
  • Cross-Sectional Studies
  • DNA Mutational Analysis
  • ErbB Receptors / genetics*
  • Gene Expression Profiling
  • Genetic Predisposition to Disease / genetics
  • Humans
  • Incidence
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / epidemiology*
  • Lung Neoplasms / genetics*
  • Molecular Targeted Therapy
  • Oncogene Proteins, Fusion / genetics*
  • Prognosis
  • Risk Factors
  • Smoking / adverse effects*
  • Smoking / epidemiology*
  • Translocation, Genetic / genetics*

Substances

  • Antineoplastic Agents
  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • EGFR protein, human
  • ErbB Receptors